Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on May 27, 2023 2:14am
166 Views
Post# 35466952

RE:RE:RE:AACR Poster - very interesting

RE:RE:RE:AACR Poster - very interesting

So my take on their thought process (I'll be easily knocked from this with any new info)

There is a serious lack of partial responses but the SD suggest they are possible. This is the reason for the pause.

Even though you're not half way through the part 2 trial there's a strong risk of getting to the end of part 2 without the requisite PRs. This might be a fatal blow to the program. Funding another go from a complete failure would be a serious struggle. So pause the trial, take the hit, tweak, shrink your target cancer types which maybe also means increasing the number of patients in each cancer, be more selective with patients and start again. Maybe give yourself an increased chance of not failing.

The Negative Nelly me would have this as them fearing to take the final fatal step. The optimist would say the tweaks could give them a chance to deliver PRs in place of SDs, I guess that's the hope. It's an uphill struggle from here though.

At least it keeps looking more likely they will actually restart.

Wino115 wrote: They got all the data together for the new protocal and the Scientific Adv Committee review and decision on whether to proceed and how. Typically you'd compile for a paper, but perhaps since they had to compile it all for the revision, FDA and that SAC, that is the data the investigator decided to publish and talk about.  I was certain they would only cover the first part of the trial since that followed the procedures and they had 100% of the data from it.  I thougth they'd skip the second part since it was partial data and then just do one more after that data was fully gathered.  So this is a surprise to me that they are reviewing all 38 patients that were on it for a few cycles. Will be really interesting to see the data now just to see what they are basing their decisions on. 

 

<< Previous
Bullboard Posts
Next >>